中国临床药理学杂志2018，Vol.34Issue(7)：800-801,808,3.DOI:10.13699/j.cnki.1001-6821.2018.07.019
来那度胺胶囊联合贝伐珠单抗注射液治疗晚期结直肠癌的临床研究
Clinical trial of lenalidomide capsules combined with bevacizumab injection in the treatment of advanced colorectal cancer
摘要
Abstract
Objective To observe the clinical efficacy and safety of lenalidomide capsules combined with bevacizumab injection in the treatment of advanced colorectal cancer.Methods Twenty-nine patients with advanced colorectal cancer received 5 mg · kg-1 bevacizumab,once every 2 week,intravenous infusion + 25 mg · d-1 lenalidomide,qd,orally,for 21 days per cycle.All patients were treated to disease progression with 28 days per cycle.The clinical efficacy and adverse drug reactions were compared.Results In 29 patients,the overall response rate was 37.93％ (11 cases/29 cases),the disease control rate was 93.10％ (27 cases/29 cases),the average medication course was 6.25 cycles and the time of median progression-free survival was 7.68 months.The adverse drug reactions were blood system damage,renal function injury and gastrointestinal reaction.Conclusion Lenalidomide capsules combined with bevacizumab injection have a promising clinical effect in the treatment of advanced colorectal cancer for patients,and the patients can tolerate adverse drug reactions.关键词
来那度胺胶囊/贝伐珠单抗注射液/晚期结直肠癌/安全性Key words
lenalidomide capsule/bevacizumab injection/advanced colorectal cancer/safety分类
医药卫生引用本文复制引用
杨齐华,叶国良,洪晓波..来那度胺胶囊联合贝伐珠单抗注射液治疗晚期结直肠癌的临床研究[J].中国临床药理学杂志,2018,34(7):800-801,808,3.基金项目
宁波市自然科学基金资助项目(2016A610123) （2016A610123）
